CEO Salary & Executive Compensation
Eli Lilly LLY
CEO: David Ricks · Pharmaceuticals · 43,000 employees
David Ricks, CEO of Eli Lilly (LLY), was reported with $36.7M in total compensation in 2025 — the SEC-disclosed headline total ("Total" line) from the Eli Lilly DEF 14A proxy statement. The per-line-item salary, stock, and option split is disclosed inside that filing and is not reproduced or estimated here.
How Eli Lilly CEO Pay Compares
David Ricks's $36.7M SEC-disclosed total compensation is 14% above the Pharmaceuticals industry median of $32.1M across 2 tracked companies with real disclosed totals.
Source: CEO total compensation is the SEC-disclosed headline figure (iXBRL ecd:PeoTotalCompAmt) from Eli Lilly’s DEF 14A proxy statement. Per-line-item salary / stock / option splits are disclosed in the filing and are not reproduced or estimated here.
Total Compensation History
| Fiscal Year | Total Compensation (SEC-disclosed) |
|---|---|
| 2025 | $36.7M |
| 2024 | $29.2M |
| 2023 | $26.6M |
| 2022 | $21.4M |
| 2021 | $21.5M |
Figures are the headline “Total” from each year’s SEC DEF 14A Summary Compensation Table. The line-item salary / bonus / stock / option split is disclosed in the source proxy and is not reproduced or estimated here.
CEO total compensation is sourced from SEC DEF 14A proxy filings submitted to EDGAR (headline total only). The Economic Policy Institute's CEO pay analysis provides additional context on executive compensation trends across industries.
Peer CEO Compensation
More Pharmaceuticals Companies
David Ricks, CEO of Eli Lilly (LLY), was reported with $36.7M in total compensation — the SEC-disclosed headline total ("Total" line) from the company's most recent DEF 14A proxy statement. The per-line-item salary, stock, and option split is disclosed inside that filing and is not reproduced here.
Frequently Asked Questions
David Ricks, CEO of Eli Lilly (LLY), was reported with $36.7M in total compensation — the SEC-disclosed headline total ("Total" line) from the company's most recent DEF 14A proxy statement. The per-line-item salary, stock, and option split is disclosed inside that filing and is not reproduced here.
The figure above is from fiscal year 2025, as reported in Eli Lilly's SEC DEF 14A proxy statement. The compensation history table shows up to five disclosed fiscal years.
Every figure is the SEC-disclosed headline total (iXBRL ecd:PeoTotalCompAmt — the Summary Compensation Table "Total" line) from Eli Lilly's DEF 14A proxy statement filed with the U.S. Securities and Exchange Commission. We report the disclosed total only and never estimate it.
Eli Lilly employs approximately 43,000 people. The company operates in the Pharmaceuticals industry within the Healthcare sector, generating $41.3B in annual revenue.